NewcelX Ltd. (Nasdaq: NCEL) announced it has completed a Type B Pre-IND meeting with the U.S. Food and Drug Administration ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE